


# The Role of the Revolving Fund in Global Initiatives

## THE ACCESS TO COVID-19 TOOLS ACCELERATOR (ACT-A)



The Access to Covid-19 Tools Accelerator (ACT-A) is a group of global health actors (WHO, BMGF, CEPI, Gavi, Global Fund, UNITAID, Wellcome Trust), private sector partners, and other stakeholders, aligned and coordinated to promote and accelerate the development, production and equitable distribution of COVID-19 vaccines, diagnostics and therapeutics.

Based on WHO's documents: <https://www.who.int/initiatives/act-accelerator>

### The Covax Facility:

The COVID-19 Vaccine Global Access (COVAX) Facility was established to accelerate equitable access to appropriate, safe and efficacious vaccines.

**PAHO Member States were recognized as a unified bloc and PAHO RF is acknowledged as one of the procurement channels for the COVAX Facility.**

## BENEFITS FROM THE COVAX FACILITY:

The Covax facility is a risk-sharing mechanism: Pooling of demand (by countries) and supply (investing into a portfolio of multiple vaccine candidates) to ensure access of a safe and efficacious vaccines for **all countries regardless of income strata**.

It offers the best opportunity for early access to successful candidate vaccines for at least 20% of the population in an equitable allocation framework across all participating countries.

## OPPORTUNITIES FOR PAHO MEMBER STATES TO ENGAGE IN COVAX FACILITY THROUGH THE REVOLVING FUND AS A REGIONAL BLOC:

◆ Member States access to new vaccines is supported by PAHO's larger technical cooperation package from plans/forecast, logistics, cold chain, support national regulatory processes and post-marketing surveillance. Therefore, vaccines procured on behalf of Member States are:

- ◇ Efficient, safe and quality assured
- ◇ Aligned with technical recommendations and regulatory policies
- ◇ Accurately forecasted and equitably allocated
- ◇ Timely delivered

◆ It is the largest vaccine pooled mechanism in the world for self-financing developing countries and territories in the Latin America and Caribbean region, with more than 40 years of experience in improving vaccine access and affordability, advocating for Member States.